Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. lessened its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,351 shares of the pharmaceutical company’s stock after selling 78 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Vertex Pharmaceuticals were worth $1,770,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. OFI Invest Asset Management purchased a new position in Vertex Pharmaceuticals during the 3rd quarter worth approximately $25,000. Arlington Trust Co LLC lifted its position in Vertex Pharmaceuticals by 97.1% during the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 33 shares during the period. Fortitude Family Office LLC purchased a new stake in Vertex Pharmaceuticals in the fourth quarter valued at $30,000. Baystate Wealth Management LLC grew its position in Vertex Pharmaceuticals by 49.0% during the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after purchasing an additional 25 shares during the period. Finally, NBC Securities Inc. purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at about $34,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently commented on VRTX shares. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 6th. Barclays raised their price objective on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. StockNews.com upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 3rd. UBS Group dropped their price target on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating on the stock in a research report on Wednesday, April 17th. Finally, Evercore ISI upgraded shares of Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price objective for the company in a research report on Thursday, April 11th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $432.18.

Vertex Pharmaceuticals Trading Up 0.0 %

Vertex Pharmaceuticals stock traded up $0.17 during trading on Thursday, reaching $418.99. 676,004 shares of the company were exchanged, compared to its average volume of 1,228,628. The stock’s 50 day simple moving average is $407.86 and its two-hundred day simple moving average is $400.88. The company has a market capitalization of $108.29 billion, a P/E ratio of 30.16, a PEG ratio of 1.89 and a beta of 0.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78. Vertex Pharmaceuticals Incorporated has a 52-week low of $320.01 and a 52-week high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, topping the consensus estimate of $3.66 by $1.10. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The business had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.58 billion. During the same quarter in the previous year, the firm earned $2.67 EPS. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Chairman Jeffrey M. Leiden sold 2,656 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $419.51, for a total transaction of $1,114,218.56. Following the completion of the sale, the chairman now owns 27,644 shares in the company, valued at approximately $11,596,934.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Chairman Jeffrey M. Leiden sold 2,656 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $419.51, for a total transaction of $1,114,218.56. Following the completion of the transaction, the chairman now directly owns 27,644 shares in the company, valued at approximately $11,596,934.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the sale, the executive vice president now owns 55,804 shares in the company, valued at $23,755,762.80. The disclosure for this sale can be found here. Insiders have sold 12,381 shares of company stock valued at $5,203,249 over the last ninety days. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.